Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Business pharma | History Defined

Loss-making vaccine maker agrees investors 'frustrated'

A listed Aussie healthcare group, under pressure after a whopping $3.7 billion loss, has acknowledged that it needs to win back the trust of shareholders.

AAP

Nine New Drugmakers Join Trump's Pricing Pact — But the Savings Remain Unproven

Nine more drugmakers joined Trump's MFN pricing deal, but the discounts flow through Medicaid — a program Texas and Florida never expanded.

Latin Times

First baby identified through Scotland’s SMA pilot has started treatment

The condition affects an average of three to four babies a year in Scotland and about 70 infants a year across the UK.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

Florida Accuses Two of the Nation's Largest Prescription Middlemen of Colluding to Underpay the Pharmacies Filling Prescriptions

Florida sued Express Scripts and Prime Therapeutics, alleging a price-fixing deal that forced pharmacies to fill prescriptions at a loss.

Medical Daily

Walmart Agrees To Pay $50M in DOJ Settlement Over Alleged Opioid Prescriptions at Its Pharmacies

Walmart will pay $50 million to settle a DOJ lawsuit over unlawfully filled opioid prescriptions, highlighting pharmacy compliance failures.

International Business Times UK

Estrogen Patch Supply Still Falls Short of Demand While the Product Stays Off the Federal Shortage List

Manufacturers say the supply of estrogen patches cannot meet demand, but the FDA has not listed estradiol patches as in shortage. Here is why that gap matters.

Medical Daily

California's Insulin Program Still Has No Vials, No Fast Acting Product and No Factory of Its Own

CalRx sells $55 insulin pens, but vials, rapid-acting insulin, and state manufacturing are all still pending. Here is what exists now.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

France issues warning over 300,000 unsafe condoms, at risk of bursting or leaking

France has recalled and flagged nearly 300,000 potentially unsafe condoms sold through pharmacies, shops and online marketplaces after laboratory tests found products that could burst or contain perforations, prompting authorities to warn consumers about possible health risks.

The Times of India

Prescription Drug Prices Fell 3.1 Percent Over the Year, but That Number Measures Less Than You Think

Prescription drug prices posted their steepest annual drop since 1963. Here is what the index actually measures and what it leaves out.

Medical Daily

Short Sellers Are Losing Big on Palantir — Here's the Data

Palantir Technologies Inc. (NASDAQ:PLTR) has become the single biggest pain point for short sellers in a market rally that is squeezing bears across the board, according to new data from S3 Partners.

Benzinga

Costco Plans to Put Its Own Name on Medicare Advantage Plans in Two States Pending Federal Approval

Costco and nonprofit insurer SCAN plan co-branded Medicare Advantage plans in two states and a supplement in a third, pending approval.

Medical Daily

A Veterinary Sedative Has Overtaken Xylazine in the Illicit Drug Supply and Withdrawal Is the Bigger Danger

Medetomidine has passed xylazine in tested drug samples. Its withdrawal starts within hours and resists the usual hospital treatments.

Medical Daily

Drug prices have declined sharply, and Trump is taking credit. The reason behind the drop is complex

President Donald Trump has been promoting new data showing U.S. prescription drug prices fell 0.8% in July and are down 3.1% from a year ago

The Independent UK

Marjorie Taylor Greene Says Congress Knows Who Is Driving Up Drug Prices, Urges Lawmakers to Stop 'Fighting Like Drunk Football Fans'

On Monday, former Rep. Marjorie Taylor Greene (R-Ga.) backed Mark Cuban’s criticism of pharmacy benefit managers, arguing that lawmakers know about the drug-pricing problem but have failed to pursue meaningful bipartisan reforms.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

Blood plasma giant's share price revives on growth path

An Aussie healthcare giant that put up its first annual loss as a listed group has staged a strong share price rebound as investors bet that the worst is over.

The Independent UK

Justice Department watchdog to review DEA tactic that permitted deadly fentanyl to hit streets

The U.S. Justice Department's internal watchdog is reviewing a controversial DEA tactic in which agents permitted fentanyl to reach the streets to build cases against traffickers

Evening Standard

AstraZeneca ditches lung cancer treatment trial

The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.

Benzinga

Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'

China has pulled ahead of the United States in clinical drug development and supply chain, two of six domains measured in a June Cure Innovation Index survey, even as Big Pharma signs billion-dollar deals for Chinese-developed medicines.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Elizabeth Warren Says UnitedHealth, CVS Have Too Much Control Over US Healthcare—Now She Wants to Break Up the Vertical Integration

Sen. Elizabeth Warren (D-Mass) has criticized the vertical integration in the U.S. healthcare system, arguing that it leads to higher costs for patients and increased profits for large corporations.

Benzinga

Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients

Amazon.com Inc.‘s (NASDAQ:AMZN) Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access.

The Guardian - UK

Soriot should explain the curious case of AstraZeneca’s non-deal

AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders

International Business Times

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year.

Benzinga

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

Novo Nordisk A/S (NYSE:NVO) stock is trading lower on Tuesday despite the company raising its fiscal 2026 guidance.

The Guardian - UK

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling

Benzinga

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.

1 2 3 4 5

People

Marjorie Taylor Greene

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.